Bone remodeling using a three-dimensional chitosan - hydroxyapatite scaffold seeded with hypoxic conditioned human amnion mesenchymal stem cells

Michael Josef Kridanto Kamadjaja

= http://dx.doi.org/10.20473/j.djmkg.v54.i2.p68-73
Abstract views = 872 times | downloads = 480 times

Abstract


Background: Bone regeneration studies involving the use of chitosan–hydroxyapatite (Ch-HA) scaffold seeded with human amnion mesenchymal stem cells (hAMSCs) have largely incorporated tissue engineering experiments. However, at the time of writing, the results of such investigations remain unclear. Purpose: The aim of this study was to determine the osteogenic differentiation of the scaffold Ch-HA that is seeded with hAMSCs in the regeneration of calvaria bone defect. Methods: Ch-HA scaffold of 5 mm diameter and 2 mm height was created by lyophilisation and desalination method. hAMSCs were cultured in hypoxia environment (5% oxygen, 10% carbon dioxide, 15% nitrogen) and seeded on the scaffold. Twenty male Wistar rat subjects (8 – 10 weeks, 200 - 250 grams) were randomly divided into two groups: control and hydroxyapatite scaffold (HAS). Defects (similar size to scaffold size) were created in the calvaria bone of the all-group subjects, but a scaffold was subsequently implanted only in the treatment group members. Control group left without treatment. After observation lasting 1 and 8 weeks, the subjects were examined histologically and immunohistochemically. Statistical analysis was done using ANOVA test. Results: Angiogenesis; expression of vascular endothelial growth factor; bone morphogenetic protein; RunX-2; alkaline phosphatase; type-1 collagen; osteocalcin and the area of new trabecular bone were all significantly greater in the HAS group compared to the control group. Conclusion: The three-dimensional Ch-HA scaffold seeded with hypoxic hAMSCs induced bone remodeling in calvaria defect according to the expression of the osteogenic and angiogenic marker.


Keywords


bone tissue engineering; chitosan-hydroxyapatite scaffold; human amniotic mesenchymal stem cells; hypoxia

Full Text:

PDF

References


Wahba MI. Enhancement of the mechanical properties of chitosan. J Biomater Sci Polym Ed. 2020; 31(3): 350–75.

Darus F, Jaafar M. Enhancement of carbonate apatite scafold properties with surface treatment and alginate and gelatine coating. J Porous Mater. 2020; 27: 831–42.

Ariani MD, Matsuura A, Hirata I, Kubo T, Kato K, Akagawa Y. New development of carbonate apatite-chitosan scaffold based on lyophilization technique for bone tissue engineering. Dent Mater J. 2013; 32(2): 317–25.

Kamadjaja MJK, Salim S, Rantam FA. Osteogenic potential differentiation of human amnion mesenchymal stem cell with chitosan-carbonate apatite scaffold (In vitro study). Bali Med J. 2016; 5(3): 71–8.

Ardhiyanto HB. Peran hidroksiapatit sebagai bone graft dalam proses penyembuhan tulang. Stomatognatic. 2011; 8(2): 118–21.

Samarawickrama. A review on bone grafting, bone substitutes and bone tissue engineering. In: ICMHI ’18: Proceedings of the 2nd International Conference on Medical and Health Informatics. Tsukuba: Association for Computing Machinery; 2018. p. 244–51.

Dasgupta S. Hydroxyapatite Scaffolds for Bone Tissue Engineering. Bioceram Dev Appl. 2017; 7(2): 1000e110.

Budiraharjo R, Neoh KG, Kang ET. Hydroxyapatite-coated carboxymethyl chitosan scaffolds for promoting osteoblast and stem cell differentiation. J Colloid Interface Sci. 2012; 366(1): 224–32.

Kim J, Kang HM, Kim H, Kim MR, Kwon HC, Gye MC, Kang SG, Yang HS, You J. Ex vivo characteristics of human amniotic membrane-derived stem cells. Cloning Stem Cells. 2007; 9(4): 581–94.

Miki T, Lehmann T, Cai H, Stolz DB, Strom SC. Stem cell characteristics of amniotic epithelial cells. Stem Cells. 2005; 23(10): 1549–59.

Sari N, Indrani D, Johan C, Corputty J. Evaluation of chitosan-hydroxyapatite-collagen composite strength as scaffold material by immersion in simulated body fluid. J Phys Conf Ser. 2017; 884: 012116.

Zhao H, Liao J, Wu F, Shi J. Mechanical strength improvement of chitosan/hydroxyapatite scaffolds by coating and cross-linking. J Mech Behav Biomed Mater. 2021; 114: 104169.

Madihally S V., Matthew HWT. Porous chitosan scaffolds for tissue engineering. Biomaterials. 1999; 20: 1133–42.

Kadam SS, Sudhakar M, Nair PD, Bhonde RR. Reversal of experimental diabetes in mice by transplantation of neo-islets generated from human amnion-derived mesenchymal stromal cells using immuno-isolatory macrocapsules. Cytotherapy. 2010; 12(8): 982–91.

Tsuji H, Miyoshi S, Ikegami Y, Hida N, Asada H, Togashi I, Suzuki J, Satake M, Nakamizo H, Tanaka M, Mori T, Segawa K, Nishiyama N, Inoue J, Makino H, Miyado K, Ogawa S, Yoshimura Y, Umezawa A. Xenografted human amniotic membrane-derived mesenchymal stem cells are immunologically tolerated and transdifferentiated into cardiomyocytes. Circ Res. 2010; 106(10): 1613–23.

Zhang D, Jiang M, Miao D. Transplanted human amniotic membrane-derived mesenchymal stem cells ameliorate carbon tetrachloride-induced liver Ccirrhosis in mouse. PLoS One. 2011; 6(2): e16789.

Kanczler JM, Oreffo ROC. Osteogenesis and angiogenesis: the potential for engineering bone. Eur Cells Mater. 2008; 15: 100–14.

Hankenson KD, Dishowitz M, Gray C, Schenker M. Angiogenesis in bone regeneration. Injury. 2011; 42(6): 556–61.

Shi Y, Su J, Roberts AI, Shou P, Rabson AB, Ren G. How mesenchymal stem cells interact with tissue immune responses. Trends Immunol. 2012; 33(3): 136–43.

Chen G, Deng C, Li Y. TGF- β and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci. 2012; 8(3): 272–88.

Kamadjaja DB, Purwati, Rantam FA, Ferdiansyah, Pramono C. The osteogenic capacity of human amniotic membrane mesenchymal stem cell (hAMSC) and potential for application in maxillofacial bone reconstruction in vitro study. J Biomed Sci Eng. 2014; 7(8): 497–503.

Nakamura H. Morphology, function, and differentiation of bone cells. J Hard Tissue Biol. 2007; 16(1): 15–22.

Tanaka S, Matsuzaka K, Sato D, Inoue T. Characteristics of newly Formed bone during guided bone regeneration: Analysis of cbfa-1, osteocalcin, and VEGF expression. J Oral Implantol. 2007; 33(6): 321–6.


Refbacks

  • There are currently no refbacks.


View My Stats